Eli Lilly & Co.’s lung cancer drug Alimta may help lengthen lives of patients whose disease is in remission, according to a study that may lead to a new treatment strategy for the malignancy.

Patients either took Alimta or a placebo every 21 days after their disease had been controlled with a standard therapy. People taking the drug lived 3 months longer overall than those on placebo, according to the Indianapolis-based company’s research being presented today at the American Society of Clinical Oncology meeting in Orlando, Florida. To read a full article of Lilly’s Alimta May Help Lung Cancer Patients Live Months Longer, please >click< here.

To buy Alimta online, please check the product details here.